tirzepatide for high blood pressure New Study Finds Use Lowered in Patients with Obesity Tirzepatide approved for weight loss
Description
Results: Treatment with tirzepatide stimulated catabolism of BCAAs/BCKAs in BAT, as demonstrated by increased labeling of BCKA-derived metabolites, and increases in levels of byproducts of BCAA breakdown, including glutamate, alanine, and 3-hydroxyisobutyric acid (3-HIB)
J., & Bullmore, E
Although several clinical trials have been completed or are currently underway, repurposing GLP-1R agonists to treat cardiometabolic syndrome-related neurodegenerative diseases will require additional research to confirm safety and efficacy
The medication isnt typically meant to be temporary
